Last reviewed · How we verify
Azelaic Acid foam 15%
At a glance
| Generic name | Azelaic Acid foam 15% |
|---|---|
| Also known as | Finacea, AZAF 1703 |
| Sponsor | Clinical Research Center of the Carolinas |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea (PHASE1)
- Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea (PHASE3)
- Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea (PHASE2)
- Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea (PHASE2)
- A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea (PHASE3)
- Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea (PHASE4)
- To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azelaic Acid foam 15% CI brief — competitive landscape report
- Azelaic Acid foam 15% updates RSS · CI watch RSS
- Clinical Research Center of the Carolinas portfolio CI